Is IGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells?

Journal of Peptide Science

Volumn 12, Issue 11, 2006, Pages 714-720

  Herédi Szabó, Krisztina ^a   Murphy, Richard F ^a   Lovas, Sándor ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; IGnRH III; Inhibition of growth; Peptide library

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTAMYLHISTIDYLTRYPTOPHANYLSERYLTYROSYLTRYPTOPHANYLMETHIONYLGLUTAMYLPROLYLGLYCYLAMIDE; GLUTAMYLHISTIDYLTRYPTOPHANYLSERYLTYROSYLTRYPTOPHANYLMETHIONYLLYSYLPROLYLGLYCYLAMIDE; GLUTAMYLHISTIDYLTRYPTOPHANYLSERYLTYROSYLTRYPTOPHANYLMETHIONYLMETHIONYLPROLYLGLYCYLAMIDE; GLUTAMYLHISTIDYLTRYPTOPHANYLSERYLTYROSYLTRYPTOPHANYLTRYPTOPHANYLGLUTAMYLPROLYLGLYCYLAMIDE; GLUTAMYLHISTIDYLTRYPTOPHANYLSERYLTYROSYLTRYPTOPHANYLTRYPTOPHANYLLYSYLPROLYLGLYCYLAMIDE; GLUTAMYLHISTIDYLTRYPTOPHANYLSERYLTYROSYLTRYPTOPHANYLTRYPTOPHANYLMETHIONYLPROLYLGLYCYLAMIDE; GONADORELIN DERIVATIVE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FOLLICLE STIMULATING HORMONE-RELEASING FACTOR; FOLLITROPIN RELEASING FACTOR; GONADORELIN; OLIGOPEPTIDE; PEPTIDE; PEPTIDE LIBRARY; PYROGLUTAMIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; BREAST TUMOR; CELL CULTURE; CHEMISTRY; DOSE RESPONSE; DRUG SCREENING; FEMALE; METABOLISM; PATHOLOGY;

PETROMYZON MARINUS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OLIGOPEPTIDES; PEPTIDE LIBRARY; PEPTIDES; PYRROLIDONECARBOXYLIC ACID; TUMOR CELLS, CULTURED;

EID: 33750701113     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.783     Document Type: Article

References (32)

1. Meden-Vrtovec H. GnRH analog administration in patients with polycystic ovarian disease. Int. J. Gynaecol. Obstet. 1995; 50: 179-183.
2. Castelo-Branco C, Martinez de Osaba MJ, Martinez S, Fortuny A. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Metabolism 1996; 45: 24-27.
3. Zafeiriou S, Loutradis D, Michalas S. The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction. Eur. J. Contracept. Reprod. Health Care. 2000; 5: 157-167.
4. Dutta AN. Luteinizing hormone-releasing hormone (LHRH) agonists. Drugs Future 1988; 13: 43-57.
5. Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999; 20: 1247-1262.
6. Fujino M, Fukuda T, Shinagawa S, Kobayashi S, Yamazaki I, Nakayama R, Seely JH, White WF, Rippel RH. Synthetic analogs of luteinizing hormone-releasing hormone (LHRH) substituted in positions 6 and 10. Biochem. Biophys. Res. Commun. 1976; 57: 1248-1256.
7. Dutta AN. Luteinizing hormone-releasing hormone (LHRH) antagonists. Drugs Future 1988; 13: 761-787.
8. Hahn DW, McGuire JL, Vale WW, Rivier J. Reproductive/endocrine and anaphylactoid properties of an LHRH-antagonist, ORF 18260 [Ac-DNAL1(2),4FDPhe2,D-Trp3,D-Arg6]-GnRH. Life Sci. 1985; 37: 505-514.
9. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, Kavanagh J, Steger M, Schulz KD, Emons G. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 2003; 90: 552-559.
10. Sower SA, Chiang Y-C, Lovas S, Conlon JM. Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain. Endocrinol. 1993; 132: 1125-1131.
11. Lovas S, Palyi I, Vincze B, Horvath J, Kovacs M, Mezo I, Toth G, Teplan I, Murphy RF. Direct anticancer activity of gonadotropin-releasing hormone-III. J. Pept. Res. 1998; 52: 384-389.
12. Kovacs M, Seprodi J, Koppan M, Horvath JE, Vincze B, Teplan I, Flerko B. Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol. 2002; 14: 647-655.
13. Palyi I, Vincze B, Lovas S, Mezo I, Pato J, Kalnay A, Turi G, Mihalik R, Peter I, Teplan I, Murphy RF. Gonadotropin-releasing hormone analogue conjugates with strong antitumor activity. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 2361-2366.
14. Kalnay A, Palyi I, Vincze B, Mihalik R, Mezo I, Palo J, Seprodi J, Lovas S, Murphy RF. Influence on antiproliferative activity of structural modification and conjugation of gonadotropin-releasing hormone (GnRH) analogues. Cell Prolif. 2000; 33: 275-285.
15. Dubois EA, Zandbergen MA, Peute J, Goos HJT. Evolutionary development of three gonadotropin-releasing hormone (GnRH) systems in vertebrates. Brain Res. Bull. 2002; 57: 413-418.
16. Gorbman A, Sower SA. Evolution of the role of GnRH in animal (Metazoan) biology. Gen. Comp. Endocrinol. 2002; 134: 207-213.
17. Limonta P, Moretti RM, Montagnani-Marelli M, Motta M. The biology of gonadotropin-releasing hormone: role in the control of tumor growth and progression in humans. Front. Neuroendocrinol. 2003; 24: 279-295.
18. Manetta A, Gamboa-Vujicic G, Paredes P, Emma D, Liao S, Leong L, Asch B, Schally A. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertil Steril. 1995; 63: 282-287.
19. Grundker C, Volker P, Schulz KD, Emons G. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol. Oncol. 2000; 78: 194-202.
20. Tang X, Yano T, Osuga Y, Matsumi H, Yano N, Xu J, Wada O, Koga K, Kugu K, Tsutsumi O, Schally AV, Taketani Y. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J. Clin. Endocrinol. Metab. 2002; 87: 3721-3727.
21. Segal-Abramson T, Kitroser H, Levy J, Schaly AV, Sharoni Y. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1992; 15: 2336-2339.
22. Heredi-Szabo K, Lubke J, Toth G, Murphy RF, Lovas S. Importance of the central region of lamprey gonadotropin-releasing hormone III in the inhibition of breast cancer cell growth. Peptides 2005; 26: 419-422.
23. Gorbman A, Sower SA. Evolution of the role of GnRH in animal (Metazoan) biology. Gen. Comp. Endocrinol. 2003; 134: 207-213.
24. Fromme BJ, Katz AA, Roeske RW, Millar RP, Flanagan CA. Role of aspartate 7.32(302) of the human gonadotropin-releasing hormone receptor in stabilizing a high-affinity ligand conformation. Mol. Pharmacol. 2001; 60: 1280-1287.
25. Maiti K, Li JH, Wang AF, Acharjee S, Kim WP, Im WB, Kwon HB, Seong JY. GnRH-II analogs for selective activation and inhibition of non-mammalian and type-II mammalian GnRH receptors. Mol. Cells. 2003; 16: 173-179.
26. Wang AF, Li JH, Maiti K, Kim WP, Kang HM, Seong JY, Kwon HB. Preferential ligand selectivity of the monkey type-II gonadotropin-releasing hormone (GnRH) receptor for GnRH-2 and its analogs. Mol. Cell. Endocrinol. 2003; 209: 33-42.
27. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz K-D, Schally AV. High affinity binding and direct antiproliferative effects of GnRH analogues in human ovarian cancer cells. Cancer Res. 1993; 52: 5439-5446.
28. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz K-D, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab. 1993; 77: 1458-1464.
29. Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur. J. Endocrinol. 2004; 151: 141-149.
30. Grundker C, Volker P, Emons G. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinol. 2001; 142: 2369-2380.
31. Maiti K, Oh DY, Moon JS, Acharjee S, Li JH, Bai DG, Park HS, Lee K, Lee YC, Jung NC, Kim K, Vaudry H, Kwon HB, Seong JY. Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death. J. Clin. Endocrinol. Metab. 2005; 90: 4287-4298.
32. Grundker C, Gunthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J. Clin. Endocrinol. Metab. 2002; 87: 1427-1430.